Alpha Cognition

Evidence of pricing power is limited today. The class is highly genericized and price sensitive. ZUNVEYL’s list and net pricing must clear payer hurdles, and while two large Medicare PBMs have contracted with no PA, downstream plan implementation is only about 16 percent so far.

Product gross margin exceeds 90 percent, which is attractive, but is not the same as customer willingness to absorb higher net pricing. Real‑world datasets in 2026 are the critical lever to justify any premium via lower GI AEs, simplified administration in LTC, or behavioral benefits; without such evidence, pricing latitude remains modest.